NCT02282527 - A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Alpha₁-Antitrypsin Deficiency

Interventions

BIOLOGICAL

Liquid Alpha₁-PI

Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions

BIOLOGICAL

Prolastin-C

Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions

Trial Locations (6)

PMG Research of Wilmington, Wilmington

University of Florida Gainesville, Gainesville

University of Miami - Miller School of Medicine, Miami

University of Texas Health Science Center, Tyler

National Jewish Health, Denver

Oregon Health and Science University, Portland